Prokidney highlights key registrational program elements supporting advancement of react®

Winston-salem, n.c., may 03, 2022 (globe newswire) -- prokidney lp (prokidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (ckd) and the prevention of both end-stage renal disease (esrd) and the need for dialysis, today highlighted the key registrational program elements supporting development of its autologous cell therapy react® for diabetic ckd. the design of the phase 3 program for react® is a result of our consultation with the food & drug administration (fda) for this first in class cellular therapy being developed to restore kidney function in patients with ckd.
PROK Ratings Summary
PROK Quant Ranking